BioVersys AGXSWX:BIOV +1.17%4 Current Ratio is 10.10 as of Dec. 2025, which is 48% above its 10-year median of 6.83. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 1,413 Biotechnology companies, BioVersys AG ranks better than 77.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioVersys AG's current ratio for the quarter that ended in Dec. 2025 was 10.10.
BioVersys AG has a current ratio of 10.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BioVersys AG's Current Ratio or its related term are showing as below:
XSWX:BIOV'
s Current Ratio Range Over the Past 10 Years
Min: 3.56 Med: 6.83 Max: 10.1
Current: 10.1
During the past 2 years, BioVersys AG's highest Current Ratio was 10.10. The lowest was 3.56. And the median was 6.83.
XSWX:BIOV's Current Ratio is ranked better than 77.92% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs XSWX:BIOV: 10.10
BioVersys AG (XSWX:BIOV) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BioVersys AG Current Ratio Related Terms
BioVersys AG Current Ratio Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Current Ratio Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Current Ratio
3.56
10.10
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Current Ratio
0.00
3.56
9.24
10.10
XSWX:BIOV vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, BioVersys AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (XSWX:BIOV) has a Current Ratio of 10.10 as of Dec. 2025. This is 48% above median its historical median of 6.83. Over the past decade, BioVersys AG's Current Ratio has ranged from 3.56 to 10.10. According to the industry distribution chart, BioVersys AG ranks #312 out of 1413 companies in the Biotechnology industry, placing it in the top 22.1%.
Is BioVersys AG's Current Ratio too high?
BioVersys AG's current Current Ratio of 10.10 is 48% above median its 10-year median of 6.83. Over the past 10 years, this metric has ranged from a low of 3.56 to a high of 10.10. The Biotechnology industry median Current Ratio is 3.89. BioVersys AG's value of 10.10 is 159.6% above this industry median. Based on the distribution chart, BioVersys AG ranks #312 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #312 out of 1413 companies for Current Ratio. This places BioVersys AG in the top 22% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. BioVersys AG's value of 10.10 is 159.6% above this benchmark. Historically, BioVersys AG's own Current Ratio has ranged from 3.56 to 10.10 over the past decade. While the company's 10-year median is 6.83 vs. the industry median of 3.89, BioVersys AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioVersys AG's current Current Ratio of 10.10 is 159.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current Current Ratio is 10.10, which is 48% above median its own 10-year median of 6.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Current Ratio of 10.10. The current Current Ratio is 10.10, which is 48% above median its 10-year median of 6.83 and 159.6% above the Biotechnology industry median of 3.89. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Current Ratio is 10.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 